Advanced Medical Isotope Reports $2.91M Loss on $30K Revenue, 18.5% Insider Stake
Advanced Medical Isotope’s insiders own 18.5% while analysts assign it a zero rating score; the company reported a net loss of $2.91 million on just $30,000 revenue with net margins of –6,144.9% and a price/sales ratio exceeding 1,038.5. Its return on assets was –113.56%, underperforming Stellus Capital on nine metrics.
1. Ownership and Institutional Support
Advanced Medical Isotope (RDGL) exhibits a concentrated ownership profile, with insiders controlling 18.5% of outstanding shares. This level of insider investment signals strong executive confidence in the company’s strategic direction and long-term prospects. Although institutional ownership data for RDGL is limited in public filings, the high insider stake may deter short-term volatility and align management incentives with shareholder value creation.
2. Financial Performance and Profitability Challenges
For the most recent reporting period, Advanced Medical Isotope generated gross revenues of approximately $30,000 but recorded a net loss of $2.91 million. The company’s net margin stands at an exceptionally negative 6,144.9%, reflecting significant R&D and operating expenditures relative to minimal commercial sales. Return on assets is negative 113.56%, underscoring the current lack of asset utilization efficiency as the business scales its radioisotope development pipeline.
3. Valuation Metrics and Liquidity Considerations
Advanced Medical Isotope’s price-to-sales ratio exceeds 1,000, indicating that the market currently values the company at a substantial premium to its low revenue base. The absence of a calculable price-earnings ratio underscores the absence of profitability. Investors should weigh this speculative valuation against the nascent stage of the company’s yttrium-90 RadioGel and veterinary isotope products, which have yet to generate meaningful cash flow or regulatory approvals.
4. Volatility, Risk Profile and Strategic Outlook
The company’s beta of –0.50 suggests its share price moves inversely to the broader market, creating unique hedging characteristics but also signaling potential liquidity constraints and thin trading volumes. As RDGL advances its brachytherapy platform toward clinical validation and FDA clearance, successful trial milestones and partnership agreements will be critical catalysts. Conversely, delay in regulatory filings or manufacturing scale-up could exacerbate cash burn and heighten financing risk.